New Lipid Biomarkers Found in Mild Cognitive Impairment Mild cognitive impairment (MCI) represents an early stage in the progression toward dementia, making early detection critical for intervention and care planning. Recent research has identified specific lipid biomarkers in saliva, plasma and feces that may improve diagnostic accuracy for MCI. These findings highlight the growing role of lipidomics in understanding neurodegeneration and offer potential pathways for non-invasive screening tools. Lipid Alterations Across Biological Samples A study conducted as part of the Microbiome in Aging Gut and Brain (MiaGB) consortium analyzed lipid profiles in older adults with MCI and healthy controls. Using high-performance liquid chromatography coupled with high-resolution mass spectrometry (LC/MS), researchers annotated over 200 molecular species across five major lipid classes. Compared to controls, individuals with MCI showed increased oxidized triacylglycerols (oxTGs) in saliva, reduced cholesteryl linoleate (CE 18:2) in plasma, and decreased fatty acid esters of hydroxy fatty acids (FAHFAs) in feces. These consistent alterations across multiple sample types suggest systemic lipid dysregulation associated with early cognitive changes. The presence of oxidized lipids in saliva may reflect oxidative stress processes, even as reduced CE 18:2 in plasma indicates alterations in cholesterol metabolism. Lower fecal FAHFA levels point to potential disruptions in gut lipid handling or microbial metabolism. Discriminatory Metabolites Identified Receiver operating characteristic (ROC) analysis identified three metabolites with strong diagnostic performance: α-linolenic acid (FA 18:3), docosapentaenoic acid (FA 22:5), and cholesteryl linoleate (CE 18:2). These compounds demonstrated notable ability to distinguish between MCI patients and healthy controls, supporting their potential as biomarkers. Elevated levels of fecal triacylglycerols containing medium-chain fatty acids (TG-MCFAs) were observed in the MCI group. This finding may indicate impaired lipid absorption or altered intestinal metabolism, further linking gut lipid dynamics to brain health. Implications for Diagnosis and Research The multi-sample lipidomics approach reveals that no single fluid or tissue provides a complete picture, but combined analysis enhances biomarker discovery. TG-MCFAs in feces, in particular, emerge as a promising non-invasive indicator for MCI detection. These results support the require for longitudinal studies to determine whether lipid changes precede cognitive decline or occur as a consequence of early neurodegeneration. By identifying measurable lipid shifts in accessible biological samples, this research advances the possibility of developing simple, cost-effective screening methods for early cognitive impairment. Continued validation in larger, diverse populations will be essential to translate these findings into clinical practice.
22